{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:48:05Z","timestamp":1792126085046,"version":"4.4.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jdcr.2026.07.037","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:15:53Z","timestamp":1785341753000},"page":"12-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Erythema multiforme-like drug eruption in a patient with mycosis fungoides on durvalumab and lenalidomide"],"prefix":"10.1016","volume":"76","author":[{"given":"Liliana L.","family":"Crisan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeralyn","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Querfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jdcr.2026.07.037_bib2","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/bloodadvances.2024014655","article-title":"Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed\/refractory cutaneous T-cell lymphoma","volume":"9","author":"Querfeld","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jdcr.2026.07.037_bib3","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2024-205617","article-title":"Randomized phase 2 trial of the anti-PD-L1 monoclonal antibody durvalumab plus lenalidomide versus single-agent durvalumab in patients with refractory\/advanced cutaneous T cell lymphoma","volume":"144","author":"Querfeld","year":"2024","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jdcr.2026.07.037_bib4","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163518","article-title":"Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma","volume":"8","author":"Han","year":"2023","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.jdcr.2026.07.037_bib5","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2013-09-525915","article-title":"Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome","volume":"123","author":"Querfeld","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jdcr.2026.07.037_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jdcr.2026.07.037_bib7","article-title":"Cutaneous adverse events of immune checkpoint inhibitors: a literature review","volume":"11","author":"Apalla","year":"2021","journal-title":"Dermatol Pract Concept"},{"issue":"6","key":"10.1016\/j.jdcr.2026.07.037_bib8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jaad.2024.08.021","article-title":"Erythema multiforme associated with the immune checkpoint inhibitors: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting system","volume":"91","author":"Godfrey","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2026.07.037_bib9","first-page":"1","article-title":"Erythema multiforme-like skin reaction induced by lenalidomide","volume":"2013","author":"Kronschl\u00e4ger","year":"2013","journal-title":"J Allergy Ther"},{"issue":"20","key":"10.1016\/j.jdcr.2026.07.037_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70324","article-title":"Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: a systematic review and meta-analysis","volume":"13","author":"Xu","year":"2024","journal-title":"Cancer Med"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626004571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626004571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:27:55Z","timestamp":1792124875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626004571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":9,"alternative-id":["S2352512626004571"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.07.037","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erythema multiforme-like drug eruption in a patient with mycosis fungoides on durvalumab and lenalidomide","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.07.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}